Celldex Therapeutics (NASDAQ:CLDX) Price Target Raised to $53.00

Дата публикации: 10-08-2026 06:00:48

Celldex Therapeutics (NASDAQ:CLDX – Free Report) had its price target raised by Barclays from $48.00 to $53.00 in a research note released on Friday morning,Benzinga reports. They currently have an overweight rating on the biopharmaceutical company’s stock. A number of other equities research analysts have also recently weighed in on CLDX. Wall Street Zen raised […]

Схожие новости

#	Наименование новости	Тональность	Информативность	Дата публикации
1	Royalty Pharma (NASDAQ:RPRX) Price Target Raised to $62.00	0	13.82	10-08-2026
2	Fidelity National Financial (NYSE:FNF) Price Target Raised to $54.00	0	11.13	10-08-2026
3	Piper Sandler Cuts Celsius (NASDAQ:CELH) Price Target to $36.00	0	12.64	10-08-2026
4	Cadre (NYSE:CDRE) Price Target Raised to $45.00	0	13.85	10-08-2026
5	Definium Therapeutics’ (DFTX) “Overweight” Rating Reiterated at Piper Sandler	0	8.75	10-08-2026
6	Chime Financial (NASDAQ:CHYM) Price Target Raised to $33.00	0	13.43	10-08-2026
7	Becton, Dickinson and Company (NYSE:BDX) Price Target Raised to $175.00	0	12.26	10-08-2026
8	BioMarin Pharmaceutical (NASDAQ:BMRN) Price Target Raised to $60.00	0	12.21	10-08-2026
9	Cleanspark’s (CLSK) “Overweight” Rating Reiterated at Cantor Fitzgerald	0	7.11	10-08-2026
10	Unity Software (NYSE:U) Price Target Raised to $55.00	0	12.66	10-08-2026

Классификация: Пресс-релизы. Схожих патентов: 0. Схожих новостей: 10. Тональность: 0. Информативность: 11.84. Источник: www.americanbankingnews.com.